SAN ANTONIO (EGMN) - The estrogen receptor antagonist fulvestrant demonstrated enhanced efficacy and good tolerability at twice the approved 250-mg dose in the phase II Neoadjuvant Endocrine Therapy for Women with Estrogen-Sensitive Tumors (NEWEST) trial."This suggests that perhaps high-dose fulvestrant could offer additional benefits to postmenopausal women with estrogen receptor-positive advanced breast cancer over the approved dose," study investigator Dr. Irene Kuter said at the San Antonio Breast...